Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Introduction: TREM2 is involved in the regulation of inflammatory response and phagocytosis. A soluble fragment (sTREM2) is often found abnormally increased in cerebrospinal fluid (CSF) in Alzheimer's disease (AD). Methods: One hundred fourteen participants (45 control, 19 preclinical, 27 mild cognitive impairment [MCI], and 23 AD) underwent CSF sTREM2 determination and magnetic resonance imaging (MRI). We studied the association between CSF sTREM2, gray matter volume, and water motion diffusivity and anisotropy across groups. Results: In MCI patients, a positive correlation between CSF sTREM2 and gray matter volume was found in the bilateral inferior and middle temporal cortices, precuneus, the supramarginal, and angular gyri, after controlling by age, sex, and p‐tau. A negative correlation with mean diffusivity was detected in overlapping regions, among others. Discussion: In early AD, augmented CSF sTREM2 levels correspond with cerebral MRI features typical of brain swelling, supporting a role for TREM2 in the regulation of the neuroinflammatory response to early neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Patients of mild cognitive impairment due to AD with high likelihood (MCI; N 5 27) were defined according to the NIA-AA criteria [2,47].”
MethodSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“These two phenotypes represent two extremes of microglial activation and a range of different phenotypes may exist between them [5].”
BackgroundA reproducible evaluation of ANTs similarity metric performance in brain image registration
Avants, B. B., Tustison, N. J., Song, G., Cook, P. A., Klein, A., & Gee, J. C. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.09.025 · Cited by 4,796
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 3×
“R47H variant is associated to increased risk of developing AD [18,19] and higher CSF levels of sTREM2 [30].”
BackgroundDiffusion tensor imaging of the brain
Alexander, A. L., Lee, J. E., Lazar, M., & Field, A. S. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.011 · Cited by 2,747 · cited 1×
“Little work has been done to characterize the relationships between DWI measures and inflammation or edema, beyond stroke, and demyelinating pathologies [63].”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“R47H variant is associated to increased risk of developing AD [18,19] and higher CSF levels of sTREM2 [30].”
BackgroundJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 6×
“Initially, decreased CSF sTREM2 levels were reported in AD patients [27].”
BackgroundMethodInfluentialSelf-citationTREMs in the immune system and beyond
Colonna, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1106 · Cited by 701
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 1×
“Homozygous mutations in TREM2 cause Nasu–Hakola disease and frontotemporal-like syndrome, an early-onset recessive form of dementia [25,26].”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522 · cited 6×
“The sTREM2 measurements used in the present study were previously published in the context of a broader multicenter study [32].”
BackgroundMethodResultInfluentialSelf-citationYKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475
Bouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460
A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease
Sexton, C. E., Kalu, U. G., Filippini, N., Mackay, C. E., & Ebmeier, K. P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.019 · Cited by 410 · cited 1×
“In AD, MD increases have been systematically reported [40] and occur before FA decrements [41–43].”
BackgroundRayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Schmid, C. D., Sautkulis, L. N., Danielson, P. E., Cooper, J., Hasel, K. W., Hilbush, B. S., Sutcliffe, J. G., & Carson, M. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01243.x · Cited by 351
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 3×
“However, it must be noted that different TREM2 variants show drastically opposite effects on CSF sTREM2 levels, thus suggesting to exert distinct disease mechanisms [27,30].”
BackgroundResultDAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features
Paloneva, J., Mandelin, J., Kiialainen, A., Böhling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, Y. T., & Peltonen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030027 · Cited by 318
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · cited 1×
“By contrast, two independent studies later reported increased CSF sTREM2 concentrations in AD patients [30,31].”
ResultDiffusion tensor imaging and aging—A review.
Moseley, M. (2002) · NMR in Biomedicine · doi:10.1002/nbm.785 · Cited by 302
Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296
Pattern Recognition by TREM-2: Binding of Anionic Ligands
Daws, M. R., Sullam, P. M., Niemi, E. C., Chen, T. T., Tchao, N. K., & Seaman, W. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.594 · Cited by 291
Bosch, B., Arenaza-Urquijo, E. M., Rami, L., Sala-Llonch, R., Junqué, C., Solé-Padullés, C., Peña-Gómez, C., Bargalló, N., Molinuevo, J. L., & Bartrés-Faz, D. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.004 · Cited by 272
Self-citationTREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247 · cited 1×
“In the central nervous system, TREM2 is selectively expressed in microglia [12,13] and plays a role in the phagocytosis of bacteria and apoptotic material [14–17].”
BackgroundTREM2 and the neuroimmunology of Alzheimer's disease
Hickman, S. E., & El Khoury, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.021 · Cited by 221
Gass, A., Niendorf, T., & Hirsch, J. G. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00487-7 · Cited by 178 · cited 1×
“MD (also referred to as apparent diffusion coefficient or ADC) represents the overall cellular integrity, whereas FA is considered to be a marker of axonal integrity and myelination [39].”
BackgroundHeterozygous TREM2 mutations in frontotemporal dementia
Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., Fenoglio, C., Piaceri, I., Archetti, S., Bonvicini, C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.017 · Cited by 173
Guerreiro, R., Bilgic, B., Guven, G., Brás, J., Rohrer, J., Lohmann, E., Hanagasi, H., Gurvit, H., & Emre, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.005 · Cited by 158
Lue, L., Schmitz, C. T., Serrano, G., Sue, L. I., Beach, T. G., & Walker, D. G. (2015) · Brain Pathology · doi:10.1111/bpa.12190 · Cited by 154 · cited 1×
“Indeed, previous postmortem studies have found increased TREM2 expression in the temporal cortex of AD patients, in association with increased tau pathology [59].”
BackgroundYasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148
Kantarci, K., Schwarz, C. G., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Zuk, S. M., Senjem, M. L., Gunter, J. L., Lowe, V., Machulda, M. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1482 · Cited by 88 · cited 1×
“In preclinical AD subjects, no significant changes in MD or FA have been detected [44,45].”
BackgroundThe application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69 · cited 1×
“In contrast, no such strong relationship has been found between brain atrophy and alterations in Ab42 biomarkers [34].”
BackgroundFrontobasal gray matter loss is associated with the TREM2 p.R47H variant
Luis, E. O., Ortega-Cubero, S., Lamet, I., Razquin, C., Cruchaga, C., Benitez, B. A., Lorenzo, E., Irigoyen, J., Pastor, M. A., & Pastor, P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.007 · Cited by 47 · cited 1×
“R47H carriers together with significantly lower MMSE values at similar disease durations, suggesting that this variant leads to a more aggressive disease progression [62].”
Background
Cited by
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationTREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Soluble TREM2 induces inflammatory responses and enhances microglial survival
Zhong, L., Chen, X.-F., Wang, T., Wang, Z., Liao, C., Wang, Z., Huang, R., Wang, D., Li, X., Wu, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160844 · Cited by 362
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
Ewers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327
“…are consistent with those of a recent study where higher CSF sTREM2 concentrations were associated with higher cortical gray matter integrity at the MCI stage ( 27 ), suggesting a potentially beneficial function of the TREM2-related immune response, particularly in the symptomatic phase of AD.”
Self-citation
Metadata
- Authors
- Gispert, J. D., Suárez‐Calvet, M., Monté, G. C., Tucholka, A., Falcon, C., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., Haass, C., & Molinuevo, J. L.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-07-13
- Volume
- 12
- Issue
- 12
- Pages
- 1259-1272
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2471281674
- Cited by
- 115
- References
- 37
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.